Alkermes plc's latest marketcap:
As of 07/05/2025, Alkermes plc's market capitalization has reached $4.76 B. According to our data, Alkermes plc is the 3453th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 4.76 B |
| Revenue (ttm) | 1.51 B |
| Net Income (ttm) | 352.71 M |
| Shares Out | 164.9 M |
| EPS (ttm) | 2.09 |
| Forward PE | 16.19 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/23/2025 |
Alkermes plc's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $4.76 B | 2.23% | 3453 |
| 12/31/2024 | $4.65 B | 0.52% | 3166 |
| 12/29/2023 | $4.63 B | 7.82% | 3042 |
| 12/30/2022 | $4.29 B | 14.15% | 3046 |
| 12/31/2021 | $3.76 B | 18.47% | 4035 |
| 12/31/2020 | $3.18 B | -1.2% | 3984 |
| 12/31/2019 | $3.21 B | -29.92% | 3321 |
| 12/31/2018 | $4.59 B | -45.52% | 2185 |
| 12/29/2017 | $8.42 B | -0.36% | 1518 |
| 12/30/2016 | $8.45 B | -29.09% | 1197 |
Company Profile
About Alkermes plc
Alkermes plc is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative pharmaceutical products. The company focuses on addressing unmet medical needs in therapeutic areas across the United States, Ireland, and internationally.
Key Therapeutic Areas
- Alcohol dependence
- Opioid dependence
- Schizophrenia
- Bipolar I disorder
- Neurological disorders
Market-Leading Products
Alkermes offers a robust portfolio of proprietary commercial products, including:
- ARISTADA – An intramuscular injectable suspension for schizophrenia treatment.
- ARISTADA INITIO – Designed for adults with schizophrenia.
- VIVITROL – Used for alcohol dependence treatment and opioid dependence prevention.
- LYBALVI – An oral atypical antipsychotic for schizophrenia and bipolar I disorder.
Technology & Collaborations
The company provides proprietary technology platforms to third parties, enabling them to develop, commercialize, and manufacture advanced pharmaceutical products. Alkermes has strategic collaborations with industry leaders, including:
- Janssen Pharmaceutica N.V.
- Janssen Pharmaceutica Inc
- Janssen Pharmaceutica International
Founded: 1987 | Headquarters: Dublin, Ireland
Frequently Asked Questions
-
What is Alkermes plc's (ALKS) current market cap?As of 07/05/2025, Alkermes plc (including the parent company, if applicable) has an estimated market capitalization of $4.76 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Alkermes plc (ALKS) rank globally by market cap?Alkermes plc global market capitalization ranking is approximately 3453 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.